Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28809818 | 1.00 | ERN1 (0.32) | ERN1MAPTCYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL16612431 | 1.00 | ERN1 (0.32) | ERN1MAPTCYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL16612396 | 0.84 | APP (0.45) | MAPTPTPN1 | |
| SCHEMBL23931215 | 0.84 | APP (0.45) | MAPTPTPN1 | |
| SCHEMBL16612400 | 0.84 | APP (0.45) | MAPTPTPN1 | |
| SCHEMBL23931214 | 0.84 | APP (0.45) | MAPTPTPN1 | |
| SCHEMBL23931216 | 0.84 | APP (0.45) | MAPTPTPN1 | |
| SCHEMBL16612399 | 0.84 | APP (0.45) | MAPTPTPN1 | |
| Sp-8356 SCHEMBL23931221 | 0.81 | TUBB1 (0.43) | MAPTCYP3A4ALDH1A1SMN1; SMN2KDM4E | |
| Sp-8356 SCHEMBL16612827 | 0.81 | TUBB1 (0.43) | MAPTCYP3A4ALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415787-A1 | COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2024-12-19 | — | — | US | claimed |
| US-10710951-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2020-07-14 | — | — | US | claimed |
| EP-2857007-B1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | UNIV KOREA RES & BUS FOUND (KR) | 2018-03-28 | — | — | EP | claimed |
| US-20170166505-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2017-06-15 | — | — | US | claimed |
| US-9603842-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2017-03-28 | — | — | US | claimed |
| US-20150148362-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-28 | — | — | US | claimed |
| US-20240415787-A1 | COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2024-12-19 | — | — | US | disclosed |
| US-10710951-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2020-07-14 | — | — | US | disclosed |
| EP-2857007-B1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | UNIV KOREA RES & BUS FOUND (KR) | 2018-03-28 | — | — | EP | disclosed |
| US-20170166505-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2017-06-15 | — | — | US | disclosed |
| US-9603842-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2017-03-28 | — | — | US | disclosed |
| US-20150148362-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | SHIN POONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-28 | — | — | US | disclosed |
| EP-2857007-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | Korea University Research and Business Foundation (KR) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166505-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | CASP3, DCX, BAX | ERN1 3558/4885MAPT 239/4885CYP3A4 1673/4885 |
| US-10710951-B2 | Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease | CASP3, DCX, BAX | ERN1 3558/4885MAPT 239/4885CYP3A4 1673/4885 |
| US-20240415787-A1 | COMPOSITION FOR TREATING OR PREVENTING OBESITY OR OBESITY-ASSOCIATED LIVER DISEASE, COMPRISING VERBENONE DERIVATIVES | SMAD3, TGFB1, TGFB2 | ERN1 2405/4885MAPT 1093/4885CYP3A4 1452/4885 |
| US-20150148362-A1 | PHARMACEUTICAL COMPOSITION CONTAINING VERBENONE DERIVATIVE FOR TREATING OR PREVENTING NEURODEGENERATIVE DISEASE | CASP3, DCX, BAX | ERN1 3558/4885MAPT 239/4885CYP3A4 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.